Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms

被引：3

作者：

Mughal, Tariq I. ^{[1
]}

Vannucchi, Alessandro M. ^{[2
]}

Soverini, Simona ^{[3
]}

Bazeos, Alexandra ^{[4
]}

Tibes, Raoul ^{[5
]}

Saglio, Giuseppe ^{[6
]}

Abdel-Wahab, Omar ^{[7
]}

Pardanani, Animesh ^{[8
]}

Hehlmann, Rudiger ^{[9
]}

Barbui, Tiziano ^{[10
]}

Van Etten, Richard ^{[11
]}

Tefferi, Ayalew ^{[8
]}

Goldman, John M. ^{[4
]}

机构：

[1] Tufts Med Ctr, Boston, MA 02111 USA

[2] Univ Florence, I-50121 Florence, Italy

[3] Univ Bologna, I-40126 Bologna, Italy

[4] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England

[5] Mayo Clin Canc Ctr, Scottsdale, AZ USA

[6] Univ Turin, I-10124 Turin, Italy

[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[8] Mayo Clin, Rochester, MN USA

[9] Heidelberg Univ, Mannheim, Germany

[10] Osped Riuniti Bergamo, I-24100 Bergamo, Italy

[11] Univ Calif Irvine, Irvine, CA USA

来源：

HAEMATOLOGICA | 2014年 / 99卷 / 05期

关键词：

CHRONIC MYELOID-LEUKEMIA; DEEP MOLECULAR RESPONSE; IMATINIB; MUTATIONS; INHIBITION; THERAPY; DISCONTINUATION; PATHOGENESIS; RUXOLITINIB; BCR-ABL1;

D O I：

10.3324/haematol.2013.097832

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E797 / 801

页数：6

共 35 条

[1] The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Abboud, Camille
Berman, Ellin
Cohen, Adam
Cortes, Jorge
DeAngelo, Daniel
Deininger, Michael
Devine, Steven
Druker, Brian
Fathi, Amir
Jabbour, Elias
Jagasia, Madan
Kantarjian, Hagop
Khoury, Jean
Laneuville, Pierre
Larson, Richard
Lipton, Jeffrey
Moore, Joseph O.
Mughal, Tariq
O'Brien, Susan
Pinilla-Ibarz, Javier
Quintas-Cardama, Alfonso
Radich, Jerald
Reddy, Vishnu
Schiffer, Charles
Shah, Neil
Shami, Paul
Silver, Richard T.
Snyder, David
Stone, Richard
Talpaz, Moshe
Tefferi, Ayalew
Van Etten, Richard A.
Wetzler, Meir
Abruzzese, Elisabetta
Apperley, Jane
Breccia, Massimo
Byrne, Jenny
Cervantes, Francisco
Chelysheva, Ekaterina
Clark, R. E.
de Lavallade, Hugues
Dyagil, Iryna
Gambacorti-Passerini, Carlo
Goldman, John
Haznedaroglu, Ibrahim
Hjorth-Hansen, Henrik
Holyoake, Tessa
Huntly, Brian
le Coutre, Philipp
Lomaia, Elza
[J]. BLOOD, 2013, 121 (22) : 4439 - 4442
[2] Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Abdel-Wahab, Omar
Levine, Ross L.
[J]. BLOOD, 2013, 121 (18) : 3563 - 3572
[3] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, Michele
Deininger, Michael W.
Rosti, Gianantonio
Hochhaus, Andreas
Soverini, Simona
Apperley, Jane F.
Cervantes, Francisco
Clark, Richard E.
Cortes, Jorge E.
Guilhot, Francois
Hjorth-Hansen, Henrik
Hughes, Timothy P.
Kantarjian, Hagop M.
Kim, Dong-Wook
Larson, Richard A.
Lipton, Jeffrey H.
Mahon, Francois-Xavier
Martinelli, Giovanni
Mayer, Jiri
Mueller, Martin C.
Niederwieser, Dietger
Pane, Fabrizio
Radich, Jerald P.
Rousselot, Philippe
Saglio, Giuseppe
Saussele, Susanne
Schiffer, Charles
Silver, Richard
Simonsson, Bengt
Steegmann, Juan-Luis
Goldman, John M.
Hehlmann, Ruediger
[J]. BLOOD, 2013, 122 (06) : 872 - 884
[4] Barbui T, 2013, BLOOD, V122
[5] Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Branford, Susan
Yeung, David T.
Ross, David M.
Prime, Jodi A.
Field, Chani R.
Altamura, Haley K.
Yeoman, Alexandra L.
Georgievski, Jasmina
Jamison, Bronte A.
Phillis, Stuart
Sullivan, Brad
Briggs, Nancy E.
Hertzberg, Mark
Seymour, John F.
Reynolds, John
Hughes, Timothy P.
[J]. BLOOD, 2013, 121 (19) : 3818 - 3824
[6] Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1BCR-ABL-JAK2 Complex
Chen, Min
Gallipoli, Paolo
DeGeer, Donna
Sloma, Ivan
Forrest, Donna L.
Chan, Matthew
Lai, Damian
Jorgensen, Heather
Ringrose, Ashley
Wang, Hui Mi
Lambie, Karen
Nakamoto, Helen
Saw, Kyi Min
Turhan, Ali
Arlinghaus, Ralph
Paul, James
Stobo, Jon
Barnett, Michael J.
Eaves, Allen
Eaves, Connie J.
Holyoake, Tessa L.
Jiang, Xiaoyan
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (06): : 405 - 423
[7] Overcoming Chronic Myeloid Leukemia Stem Cell Resistance to Imatinib by Also Targeting JAK2
Cogle, Christopher R.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (06): : 378 - 379
[8] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, Brian J.
Guilhot, Francois
O'Brien, Stephen G.
Gathmann, Insa
Kantarjian, Hagop
Gattermann, Norbert
Deininger, Michael W. N.
Silver, Richard T.
Goldman, John M.
Stone, Richard M.
Cervantes, Francisco
Hochhaus, Andreas
Powell, Bayard L.
Gabrilove, Janice L.
Rousselot, Philippe
Reiffers, Josy
Cornelissen, Jan J.
Hughes, Timothy
Agis, Hermine
Fischer, Thomas
Verhoef, Gregor
Shepherd, John
Saglio, Giuseppe
Gratwohl, Alois
Nielsen, Johan L.
Radich, Jerald P.
Simonsson, Bengt
Taylor, Kerry
Baccarani, Michele
So, Charlene
Letvak, Laurie
Larson, Richard A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417
[9] A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers
Dunwell, Thomas
Hesson, Luke
Rauch, Tibor A.
Wang, Lihui
Clark, Richard E.
Dallol, Ashraf
Gentle, Dean
Catchpoole, Daniel
Maher, Eamonn R.
Pfeifer, Gerd P.
Latif, Farida
[J]. MOLECULAR CANCER, 2010, 9 : 44
[10] Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia
Flamant, Stephane
Ritchie, William
Guilhot, Joelle
Holst, Jeff
Bonnet, Marie-Laure
Chomel, Jean-Claude
Guilhot, Francois
Turhan, Ali G.
Rasko, John E. J.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (08): : 1325 - 1333

← 1 2 3 4 →